Medpace

MEDP

Market cap $12.8B

Medpace (MEDP) reached $447.09 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.

New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ: MEDP) concerning potential violations of the federal securities laws. On February 10, 2026, Medpace shares fell approximately 10% by mid-day and closed down 15.9%, according to data from Quiver Quantitative and GuruFocus.

(NASDAQ: MEDP) NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential securities law claims on behalf of shareholders. The investigation centers on whether the company and its senior officers made statements about the health of its clinical-trial booking pipeline that were inconsistent with internal data showing elevated cancellation rates and a deteriorating book-to-bill ratio.

New York, New York--(Newsfile Corp. - February 17, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ: MEDP) concerning potential violations of the federal securities laws. On February 10, 2026, Medpace shares fell approximately 10% by mid-day and closed down 15.9%, according to data from Quiver Quantitative and GuruFocus.

Large, sudden stock price swings—like Medpace's recent spike and drop—are often driven by identifiable factors such as short squeezes or concentrated trading, not pure randomness. Investors should distinguish between moves based on verifiable corporate developments and those fueled by momentum or retail trading, as each carries different risks and implications for long-term value.

Oslo, Norway – 11 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a clinical partnership with Medpace, a leading global Contract Research Organization (CRO), to support the first clinical trial of ZI-MA4-1 (ZIMA-101), Zelluna's lead product candidate.

Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript

Medpace stock slumped early Tuesday on a "significant bookings miss," outshining the company's solid fourth-quarter sales and earnings.

Medpace Holdings delivered strong Q4 and FY 2025 results, beating revenue and EPS expectations, with 32% YoY revenue growth and 27% YoY EPS growth. MEDP's backlog growth remains sluggish, but a healthy book-to-bill ratio and potential sector recovery could accelerate future growth. Valuation is now fair at ~32x P/E, with a DCF suggesting modest 6% upside; disciplined share buybacks continue to support EPS growth.

Medpace (MEDP) came out with quarterly earnings of $4.67 per share, beating the Zacks Consensus Estimate of $4.18 per share. This compares to earnings of $3.67 per share a year ago.